GlassScriptPhysician profile
Christopher D Wiggs
NPI 1366585143
$2,056.21
in general payments reported to CMS, 2019-2025
30 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.36 · 2020: $109 · 2021: $569 · 2022: $203 · 2023: $434 · 2024: $372 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $560.43 | 2019-2023 | Liletta, Vraylar, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $207.56 | 2023-2025 | |
| Hologic Sales and Service, LLC | $155.76 | 2019-2025 | Novasure, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Astellas Pharma US INC | $135.87 | 2021-2025 | Veozah |
| Daiichi Sankyo INC. | $121.35 | 2020-2022 | |
| Organon LLC | $113.24 | 2021-2025 | Nexplanon, Jada System, Nuvaring |
| Amgen INC. | $101.62 | 2020-2022 | |
| Shield Therapeutics INC | $72.34 | 2024 | |
| Fisher Scientific Company L.L.C. | $69.44 | 2024 | Procalcitonin |
| Pfizer INC. | $68.59 | 2021-2025 | |
| Lilly USA, LLC | $53.00 | 2025 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $43.28 | 2021 | |
| Novo Nordisk INC | $41.38 | 2022-2024 | Wegovy, Saxenda |
| Radius Health, INC. | $39.39 | 2019-2021 | |
| Convatec INC. | $29.01 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $28.75 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $22.29 | 2024 | Myfembree |
| Allergan, INC. | $22.02 | 2020 | |
| Innovation Technologies INC | $19.90 | 2024 | Irrisept |
| Merck Sharp & Dohme LLC | $19.70 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.48 | 2023 | |
| Channel Medsystems, INC. | $15.73 | 2025 | |
| Exeltis, USA INC. | $14.99 | 2022 | |
| Smith+Nephew, INC. | $14.38 | 2024 | Pico 7 |
| Revvity, INC. | $14.38 | 2023 | |
| Therapeuticsmd, INC. | $13.68 | 2021 | |
| Avanos Medical | $12.42 | 2019 | |
| Scynexis, INC. | $11.96 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.95 | 2022 | |
| Evofem Biosciences, INC. | $5.32 | 2025 | Phexxi, Solosec, Phexx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wiggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.